After Bloomberg reported that Mirati Therapeutics is drawing fresh takeout interest ahead of updated PD1 + adagrasib combination data at next month’s ESMO I/O meeting, BMO Capital analyst Evan Seigerman said he expects Mirati to build upon data shared in conjunction with the June ASCO meeting that showed “encouraging efficacy” when adagrasib was combined with PD1. A takeout is likely to reflect full valuation for usage in the first line NSCLC setting, said Seigerman, who could see Mirati being valued at up to $200 per share in an “upside scenario.” He has an Outperform rating and $110 price target on Mirati shares, which are up $11.90, or 16%, to $86.44 following Bloomberg’s report.